NPCE Overview

Key Data

  • Open $20.85
  • Day Range 20.18 - 21.26
  • 52 Week Range 18.24 - 27.38
  • Market Cap $479.43M
  • Shares Outstanding 22.93M
  • Public Float 9.5M
  • Beta 1.07
  • Rev. per Employee N/A
  • P/E Ratio N/A
  • EPS N/A
  • Yield N/A
  • Dividend N/A
  • Ex-Dividend Date N/A
  • Short Interest 84K 04/30/21
  • % of Float Shorted 0.88%
  • Average Volume 434.97K

Performance

5 Day
  • 4.60%

Recent News

  • MarketWatch
  • Dow Jones

NeuroPace started at overweight at Morgan Stanley

May. 17, 2021 at 12:25 p.m. ET by Tomi Kilgore

NeuroPace started at overweight with $27 stock price target at J.P. Morgan

May. 17, 2021 at 6:53 a.m. ET by Tomi Kilgore
Barron's

Zymergen and 2 Other IPOs Made Strong Market Debuts Thursday

Apr. 22, 2021 at 11:13 a.m. ET by Barron's
Barron's

Automation Software Start-Up UiPath Leads Slate of 3 IPOs

Apr. 21, 2021 at 1:02 p.m. ET by Barron's
  • Other News
  • Press Releases

No Headlines Available

NeuroPace Inc.

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.